Patients On Pfizer’s initiative to return clinical trial data to pati... Among the most common reasons for dropping out, patients cite a lack of communication about the trial
R&D Focus on the positive to stop public perception being a barr... Public misconceptions surrounding the process, its risks and its benefits remain a significant barrier to clinical trial participation, which is not surprising in a world where the only int
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
